Respiratory Syncytial Virus

A large US study found that two RSV prevention strategies, giving infants the antibody nirsevimab or vaccinating mothers during pregnancy, substantially reduced the risk of babies needing emergency or...

A prespecified DAN-RSV trial analysis found RSVpreF reduced RSV-related hospitalization regardless of heart failure status.

Dr. William Schaffner, MD, reviews evolving adult vaccination guidance and key opportunities to prevent severe disease in clinical practice.

ACOG’s 2026 maternal immunization schedule outlines vaccine recommendations before, during, and after pregnancy, including influenza, COVID-19, Tdap, and RSV vaccination.

New reports link SARS-CoV-2 and RSV to persistent cardiopulmonary risk and describe distinct postviral lung and brain changes in a mouse model.

This roundup explores updated 2024-2025 COVID-19 vaccine effectiveness data, an FDA-cleared 4-pathogen home test, and new evidence on metformin for long COVID risk.

A large pragmatic randomized trial evaluated whether a bivalent respiratory syncytial virus (RSV) prefusion F protein-based vaccine could reduce RSV-related hospitalizations among adults aged 60 years or...

New data describe durability of XBB.1.5 vaccine antibodies, platform-specific vaccine immunogenicity, CDC safety trust, and 2025 US uptake barriers.

In a nationwide Danish trial of more than 130,000 adults aged 60 years and older, a single dose of the bivalent RSV prefusion F protein vaccine reduced all-cause cardiorespiratory hospitalizations by nearly...

New studies highlight that while persistent SARS-CoV-2 infections can evolve rapidly within individuals, they rarely spread onward. Meanwhile, the 2024–2025 COVID-19 vaccine reduced mortality by 64% among...